ABBV Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

211.360

Open

210.370

VWAP

209.48

Vol

5.07M

Mkt Cap

369.98B

Low

207.680

Amount

1.06B

EV/EBITDA(TTM)

14.47

Total Shares

1.77B

435.23B

EV/OCF(TTM)

20.51

P/S(TTM)

5.94

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

Events Timeline

(ET)

2026-04-30

16:30:00

Dow Rises 790.33 Points, Nasdaq Gains 219.07 Points

2026-04-30

12:00:00

Major Averages Rebound, Nasdaq Up 0.19%

News

8.0

11:06 AMFool

Analysis of High Dividend Stocks in Healthcare Sector

8.0

11:04 AMNASDAQ.COM

Analysis of High Dividend Performance in Healthcare Stocks

5.0

05-16CNBC

Johnson & Johnson's Icotyde Shows Strong Potential as a Cash Cow

5.0

05-14Fool

Investment Strategy for High-Quality Assets

7.5

05-13Globenewswire

Oncotelic Launches Innovative Brain Drug Delivery System

8.5

05-13Globenewswire

SureNano Science Develops Next-Gen GLP-1 Therapy GEP-44

18 Analyst Rating

Wall Street analysts forecast ABBV stock price to rise

12 Buy

6 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

223.00

Averages

252.00

High

289.00

Current: 0.000

Low

223.00

Averages

252.00

High

289.00

Evercore ISI

NULL

Outperform

maintain

$236 -> $235

AI Analysis

2026-05-15

New

Reason

Evercore ISI

Price Target

$236 -> $235

AI Analysis

2026-05-15

New

maintain

NULL

Outperform

Reason

Evercore ISI lowered the firm's price target on AbbVie to $235 from $236 and keeps an Outperform rating on the shares.

Piper Sandler

Overweight

maintain

$294 -> $298

2026-05-14

New

Reason

Piper Sandler

Price Target

$294 -> $298

2026-05-14

New

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on AbbVie to $298 from $294 and keeps an Overweight rating on the shares. The depth of AbbVie's inflammatory bowel disease pipeline remains the focus of significant investor attention, the firm says. Given the white-hot nature of the IBD drug development landscape, management's advancement of novel combination approaches in IBD is undoubtedly a welcome development. That said, one of the considerations that renders AbbVie shares attractive in Piper's view is the range of R&D shots-on-goal that continue to fall under the broader investor radar.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABBV

Unlock Now

Valuation Metrics

The current forward P/E ratio for AbbVie Inc (ABBV.N) is 14.14, compared to its 5-year average forward P/E of 13.52. For a more detailed relative valuation and DCF analysis to assess AbbVie Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

13.52

Current PE

14.14

Overvalued PE

16.26

Undervalued PE

10.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

12.83

Current EV/EBITDA

13.89

Overvalued EV/EBITDA

15.90

Undervalued EV/EBITDA

9.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.99

Current PS

5.13

Overvalued PS

5.77

Undervalued PS

4.21

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

which megacap surged max yesterday

Intellectia · 64 candidates

Region: USMarket Cap Category: mega

Ticker

Name

Market Cap$

UNH

UnitedHealth Group Inc

359.98B

Philip Morris International Inc

291.34B

NFLX

Netflix Inc

369.12B

ABBV

AbbVie Inc

367.25B

LLY

Eli Lilly and Co

932.20B

COST

Costco Wholesale Corp

453.36B

what stock earnings next week

Intellectia · 133 candidates

Market Cap: >= 10.00BPrice: >= $10.00Is Index Component: GSPCMonthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

GOOG

Alphabet Inc

4.09T

MSFT

Microsoft Corp

3.09T

AMZN

Amazon.com Inc

2.74T

META

Meta Platforms Inc

1.70T

TSLA

Tesla Inc

1.47T

Find me a trade a d take i

Intellectia · 85 candidates

Region: USVolume: >= -100List Exchange: XNAS, XNYS, XASEMoving Average Relationship: PriceCrossAboveMA20, PriceCrossDownMA20, PriceAboveMA20, PriceAboveMA200, PriceBelowMA20, PriceBelowMA200Is Optionable: TrueSupport Resistance Relationship: PriceBreakResistance, PriceFallBelowSupport, PriceAroundResistance, PriceAroundSupportOne Day Rise Prob: 0 - 100One Day Predict Return: 0.0% - 100.0%One Week Rise Prob: 0 - 100One Week Predict Return: 0.0% - 100.0%Monthly Average Dollar Volume: >= -100Macd: positive, negative, bearish, bullish

Ticker

Name

Market Cap$

ABBV

AbbVie Inc

362.35B

ABT

Abbott Laboratories

182.61B

ARM

Arm Holdings PLC

145.38B

BUD

Anheuser-Busch Inbev SA

133.72B

BTI

British American Tobacco plc

125.56B

ADBE

Adobe Inc

100.95B

top stocks in health sector

Intellectia · 38 candidates

Market Cap: >= 10.00BSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, Healthcare Equipment & Supplies, Healthcare Providers & Services, PharmaceuticalsAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%

Ticker

Name

Market Cap$

LLY

Eli Lilly and Co

866.87B

ABBV

AbbVie Inc

364.65B

AZN

AstraZeneca PLC

293.00B

MRK

Merck & Co Inc

282.35B

UNH

UnitedHealth Group Inc

254.55B

AMGN

Amgen Inc

188.63B

best stocks to swing trade

Intellectia · 1222 candidates

Region: USRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Month Price Change Pct: $-5.00 - $40.00Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

TSM

Taiwan Semiconductor Manufacturing Co Ltd

1.94T

XOM

Exxon Mobil Corp

635.43B

COST

Costco Wholesale Corp

448.66B

ABBV

AbbVie Inc

410.36B

Procter & Gamble Co

390.70B

General Electric Co

358.95B

what blue chip

Intellectia · 59 candidates

Market Cap: >= 80.00BDividend Yield Ttm: 1 - 6Net Margin: >= 5.00Return On Equity: >= 10.0%Is Index Component: GSPC, DJI

Ticker

Name

Market Cap$

JPM

JPMorgan Chase & Co

809.92B

XOM

Exxon Mobil Corp

635.43B

JNJ

Johnson & Johnson

598.69B

ABBV

AbbVie Inc

410.36B

Procter & Gamble Co

390.70B

Home Depot Inc

379.01B

Stocks with same technicals as DHR

Intellectia · 52 candidates

Market Cap: >= 150.00BRegion: USRsi Category: moderateMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

NVDA

NVIDIA Corp

4.31T

AAPL

Apple Inc

3.88T

GOOG

Alphabet Inc

3.77T

AVGO

Broadcom Inc

1.52T

TSLA

Tesla Inc

1.51T

WMT

Walmart Inc

1.02T

Whales Holding ABBV

The Glenmede Trust Company, National Association

Schroder Investment Management Limited

Mubadala Investment Company PJSC

SteelPeak Wealth, LLC

Texas Yale Capital Corp.

Diversify Advisory Services, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is AbbVie Inc (ABBV) stock price today?

The current price of ABBV is 209.41 USD — it has decreased -0.47

What is AbbVie Inc (ABBV)'s business?

What is the price predicton of ABBV Stock?

Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is252.00 USD with a low forecast of 223.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is AbbVie Inc (ABBV)'s revenue for the last quarter?

AbbVie Inc revenue for the last quarter amounts to 15.00B USD, increased 12.43

What is AbbVie Inc (ABBV)'s earnings per share (EPS) for the last quarter?

AbbVie Inc. EPS for the last quarter amounts to 0.39 USD, decreased -45.83

How many employees does AbbVie Inc (ABBV). have?

AbbVie Inc (ABBV) has 57000 emplpoyees as of May 19 2026.

What is AbbVie Inc (ABBV) market cap?

Today ABBV has the market capitalization of 369.98B USD.

ABBV Overview

ABBV Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding ABBV

Trading Trends

People Also Watch

Frequently Asked Questions

What is AbbVie Inc (ABBV) stock price today?

What is AbbVie Inc (ABBV)'s business?

What is the price predicton of ABBV Stock?

What is AbbVie Inc (ABBV)'s revenue for the last quarter?

What is AbbVie Inc (ABBV)'s earnings per share (EPS) for the last quarter?

How many employees does AbbVie Inc (ABBV). have?

What is AbbVie Inc (ABBV) market cap?